table of contents intangibles 2014goodwill and other in december 2010 , the fasb issued asu 2010-28 , intangibles 2014goodwill and other ( topic 350 ) .
asu 2010-28 modifies step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts .
for those reporting units , an entity is required to perform step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists .
in determining whether it is more likely than not that a goodwill impairment exists , an entity should consider whether there are any adverse qualitative factors indicating that an impairment may exist .
asu 2010-28 is effective for the company in fiscal 2012 .
the adoption of asu 2010-28 is not expected to have a material impact on the company 2019s consolidated financial statements .
in september 2011 , the fasb issued asu no .
2011-08 , intangibles 2014goodwill and other ( topic 350 ) : testing goodwill for impairment .
asu 2011-08 allows entities to first assess qualitatively whether it is necessary to perform the two-step goodwill impairment test .
if an entity believes , as a result of its qualitative assessment , that it is more likely than not that the fair value of a reporting unit is less than its carrying amount , the quantitative two-step impairment test is required ; otherwise , no further testing is required .
asu 2011-08 is effective for the company beginning in fiscal 2013 , although early adoption is permitted .
the company does not believe that asu 2011-08 will have a material impact on its consolidated financial statements .
3 .
business combinations fiscal 2012 acquisition : gen-probe , inc .
on august 1 , 2012 , the company completed the acquisition of gen-probe and acquired all of the outstanding shares of gen-probe .
pursuant to the merger agreement , each share of common stock outstanding immediately prior to the effective time of the acquisition was cancelled and converted into the right to receive $ 82.75 in cash .
in addition , all outstanding restricted shares , restricted stock units , performance shares , and those stock options granted prior to february 8 , 2012 were cancelled and converted into the right to receive $ 82.75 per share in cash less the applicable exercise price , as applicable .
stock options granted after february 8 , 2012 were converted into stock options to acquire shares of hologic common stock determined by a conversion formula defined in the merger agreement .
the company paid the gen-probe shareholders $ 3.8 billion and $ 169.0 million to equity award holders .
the company funded the acquisition using available cash and financing consisting of senior secured credit facilities and senior notes ( see note 5 for further discussion ) resulting in aggregate proceeds of $ 3.48 billion , excluding financing fees to the underwriters .
the company incurred approximately $ 34.3 million of direct transaction costs recorded within general and administrative expenses .
gen-probe , headquartered in san diego , california , is a leader in molecular diagnostics products and services that are used primarily to diagnose human diseases , screen donated human blood , and test transplant compatibility .
the company expects this acquisition to enhance its molecular diagnostics franchise and to complement its existing portfolio of diagnostics products .
gen-probe 2019s results of operations are reported within the company 2019s diagnostics reportable segment from the date of acquisition .
the purchase price consideration was as follows: .

Cash paid
$3,967,866
Deferred payment
1,655
Fair value of stock options exchanged
2,655
Total purchase price
$3,972,176

the fair value of stock options exchanged recorded as purchase price represents the fair value of the gen-probe options converted into the company 2019s stock options attributable to pre-combination services pursuant to asc 805 , business combinations .
the remainder of the fair value of these options of $ 23.2 million will be recognized as stock-based compensation expense over the remaining vesting period , which is approximately 3.5 years .
the company estimated the fair value of the stock options using a binomial valuation model with the following weighted average assumptions : risk free rate of 0.41% ( 0.41 % ) , expected volatility of 39.9% ( 39.9 % ) , expected life of 3.6 years and dividend of 0.0% ( 0.0 % ) .
the weighted average fair value of stock options granted is $ 7.07 per share .
source : hologic inc , 10-k , november 28 , 2012 powered by morningstar ae document research 2120 the information contained herein may not be copied , adapted or distributed and is not warranted to be accurate , complete or timely .
the user assumes all risks for any damages or losses arising from any use of this information , except to the extent such damages or losses cannot be limited or excluded by applicable law .
past financial performance is no guarantee of future results. .

Question: Analyse this data from a financial earnings document. what is the expected yearly stock-based compensation expense over the remaining vesting period , ( in millions ) ?
Choices:
2320
26.7
6.62857
0.00663
1
Correct choice index: 2